<DOC>
	<DOCNO>NCT00135499</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy doxorubicin , cyclophosphamide , vindesine , bleomycin , prednisone ( ACVBP ) plus rituximab comparison cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) plus rituximab patient age 60 65 year non-previously treat diffuse large B-cell lymphoma measure event-free survival . The goal obtain 10 % increase event-free survival 3 year .</brief_summary>
	<brief_title>R-ACVBP Versus R-CHOP Patients Aged 60-65 With Diffuse Large B-Cell Lymphoma</brief_title>
	<detailed_description>In Europe , 50 % new non-Hodgkin lymphoma case occur patient old 60 year . More 30 % diffuse large B-cell lymphoma ( DLCL ) . The CHOP chemotherapy ( cyclophosphamide , doxorubicin , vincristine , prednisone ) consider standard treatment population . Nevertheless , treatment associate toxic event elderly patient succeed increase 3-year survival rate 40 % . Two trial patient 60 year DLCL case conduct GELA aim improve result CHOP . Protocol LNH 93-5 : The primary objective study compare CHOP ACVBP patient age 61 69 year aggressive lymphoma least one adverse prognostic factor accord International Prognostic Index . Unlike CHOP regimen , ACVBP regimen include intensive induction follow sequential consolidation drug different use induction phase , include prevention neuromeningeal relapse . Out 708 patient include study , result show : - Complete response rate two arm . - Event free survival significantly well ACVBP arm CHOP arm ( 5-year survival rate : 39 % versus 29 % , p=0.005 ) . - Overall survival significantly well ACVBP arm CHOP arm ( 5-year survival rate : 46 % versus 38 % , p=0.036 ) . - The ACVBP regimen toxic CHOP regimen , particularly elderly patient ( &gt; 65 year ) patient low performance status . - Prevention neuromeningeal relapse necessary patient . Protocol LNH 98-5 , objective study compare association CHOP + rituximab ( R-CHOP ) CHOP regimen alone elderly patient non previously treat diffuse large B-cell lymphoma . Long-term result base data 399 patient , median follow-up 5 year follow : - Complete response rate well R-CHOP arm CHOP arm ( 76 % versus 61 % , p &lt; 0.005 ) . - Significant prolongation event-free survival ( p &lt; 0.0002 ) overall survival ( p &lt; 0.0073 ) R-CHOP arm . - No significant difference two arm term toxicity . R-CHOP consider worldwide standard combination patient . These conclusion invite u propose randomize trial compare ACVBP + rituximab CHOP + rituximab . The study population limit patient age 60 65 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Patient diffuse large Bcell lymphoma accord WHO classification ( anti CD20 labeling ) Aged 60 65 year . Not previously treat . Ann Arbor stage II , III , IV . ECOG performance status 0 2 . Minimum life expectancy 3 month . Negative HIV , hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) serologies test  4 week ( except vaccination ) . Having previously sign write informed consent . Tcell lymphoma . Any history treat nontreated indolent lymphoma . However , patient previously diagnose diffuse large Bcell lymphoma small cell infiltration bone marrow lymph node may include . Central nervous system meningeal involvement lymphoma . Contraindication drug contain chemotherapy regimen . Any serious active disease ( accord investigator ’ decision ) . Poor renal function ( creatinine level &gt; 150micromol/l ) , poor hepatic function ( total bilirubin level &gt; 30mmol/l , transaminase &gt; 2.5 maximum normal level ) unless abnormality relate lymphoma . Poor bone marrow reserve define neutrophil &lt; 1.5G/l platelet &lt; 100G/l , unless relate bone marrow infiltration . Any history cancer last 5 year exception nonmelanoma skin tumor stage 0 ( situ ) cervical carcinoma . Treatment investigational drug within 30 day plan first cycle chemotherapy study . Adult patient tutelage .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>rituximab</keyword>
</DOC>